PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
September 26, 2025Inflammatory Bowel Diseases2 citationsOpen Access

Therapeutic Benefit of Upadacitinib in Severe Post-Proctectomy (Class 4) Perianal Crohn’s Disease: A Three-Patient Case Series

View Full Paper
LHL HannaBQBaseer QuraishiTPT Pelly

Key Points

  • Clinically significant responses were seen in all three patients treated with upadacitinib, suggesting a new therapeutic option.
  • Radiological improvements further support the positive clinical findings, particularly in resolving perianal complications.
  • Patients previously faced persistent complications post-proctectomy, underscoring the need for effective new therapies in this context.
  • The outcomes indicate that upadacitinib may address refractory cases of inflammatory bowel disease, indicating a shift in treatment strategy.

Abstract

Abstract This case series describes striking clinical and radiological responses in 3 Crohn’s disease patients with persistent perineal complications following proctectomy treated with upadacitinib. It highlights the potential of advanced therapies for this refractory inflammatory bowel disease phenotype with limited treatment options.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Hanna et al. (2025) studied this question.

synapsesocial.com/papers/68d6c671b1249cec298b2196https://doi.org/10.1093/ibd/izaf216
Ask AI
Helpful
Bookmark
Share
View Full Paper